focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment to Scientific Advisory Board

3 Sep 2014 07:00

RNS Number : 6680Q
Collagen Solutions PLC
03 September 2014
 



Collagen Solutions Plc

(the "Company" or the "Group")

 

Mr Tom Hyland joins Collagen Solutions Scientific Advisory Board.

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, is pleased to welcome Mr Tom Hyland as scientific adviser to the company.

 

Mr Hyland has a wealth of experience in the field of collagen chemistry and the development, manufacturing, validation and engineering requirements of collagen-based medical devices. He is a recognised expert in the field as a six sigma black belt, and has played a major role in bringing a number of highly successful collagen-based products to market.

 

Tom has worked with an impressive list of global life science companies, including Johnson and Johnson Wound Management where he was involved in the identification and commercialisation of a series of products which now have global sales exceeding £50m per annum. He was also employed at Microsulis, Intercell, Alere and Invitrogen, in a range of senior operational roles in the areas of Drugs, Diagnostics & Interventional Devices, manufacture scale up and production technology.

 

Such expertise is now essential as Collagen Solutions starts to develop its own proprietary products, including the technology of Professor Robert Brown at UCL that was recently licensed. Tom will be working closely with Professor Brown and the management team to identify and oversee the manufacture and development of novel collagen-based products for Collagen Solutions to commercialise.

 

Dr Stewart White, Chief Executive Officer of Collagen Solutions, said: "Tom has over 25 years of identifying and manufacturing collagen devices, diagnostics and biological products which is an ideal profile for us as we capture a greater proportion of the value chain and develop our own range of proprietary collagen products. I am delighted to welcome Tom to our scientific advisory board where he will be able to identify and create the new generation of collagen products that will create shareholder value in this rapidly growing and exciting area of regenerative medicine. Tom's common sense approach, collagen engineering pedigree and operational capabilities will add real value to our business and help accelerate company growth and help deliver our strategy and realise our vision."

 

Mr Hyland is currently the General Manager of API Foils Europe in Livingston, has a Honours Degree in Chemistry and Chemical Engineering and a MBA from Herriot Watt University.

 

 

 

Enquiries:

 

Collagen Solutions Plc

 

David Evans, Chairman 

Tel: 07740 084 452

Stewart White, CEO

Tel: 0141 558 2008

 

 

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews / John Depasquale (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

Notes to Editors:

Six Sigma

Six Sigma is a business management strategy that was initially developed by Motorola in the 1980's, and now is used in many Fortune 500 companies. It is used primarily to identify and rectify errors and defects in a manufacturing or business process in order to increase efficiencies and output.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRABLGDCRGGBGSD
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.